Ensysce Biosciences Inc

NASDAQ:ENSCUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Contact Information

Headquarters

7946 Ivanhoe Avenue, Suite 201LA JOLLA, CA, United States 92037

Phone

858-263-4196

Fax

302-636-5454

Executives

Independent Chairman of the Board

Bob Gower

President, Chief Executive Officer, Director

Lynn Kirkpatrick

Chief Financial Officer, Treasurer, Secretary

David Humphrey

Chief Operating Officer

Jeffrey Millard

Chief Commercial Officer

Geoffrey Birkett